药学学报, 2021, 56(11): 2977-2984
引用本文:
刘畅, 刘姗姗, 李云炫, 花芳, 吕晓希. 甲磺司特通过抑制GATA3介导的Th2细胞分化治疗肺纤维化[J]. 药学学报, 2021, 56(11): 2977-2984.
LIU Chang, LIU Shan-shan, LI Yun-xuan, HUA Fang, LÜ Xiao-xi. Suplatast tosilate attenuates pulmonary fibrosis by inhibiting the GATA3 induced Th2 differentiation[J]. Acta Pharmaceutica Sinica, 2021, 56(11): 2977-2984.

甲磺司特通过抑制GATA3介导的Th2细胞分化治疗肺纤维化
刘畅1,2, 刘姗姗1, 李云炫3, 花芳1, 吕晓希1*
1. 中国医学科学院、北京协和医学院药物研究所, 北京 100050;
2. 首都儿科研究所附属儿童医院, 北京 100020;
3. 中国医学科学院、北京协和医学院医药生物技术研究所, 北京 100050
摘要:
肺纤维化是威胁人类健康的慢性呼吸系统炎性疾病。肺部组织局部的免疫微环境调控了纤维化疾病进程。本研究观察了甲磺司特抗肺纤维化疗效及其生物学机制。甲磺司特是辅助性T细胞2 (T helper 2,Th2) 细胞因子抑制剂,用于临床支气管哮喘的治疗,但其是否能用于慢性肺纤维化的治疗及抑制Th2细胞因子释放的生物学机制并不清晰。通过体内及体外研究发现,甲磺斯特可以显著抑制多次博莱霉素损伤所致慢性肺纤维化发病,改善肺功能,减少肺部胶原沉积。同时甲磺司特通过抑制Th2细胞分化,显著减少Th2型细胞因子释放,但并不影响辅助性T细胞1 (T helper 1,Th1) 细胞分化及Th1型细胞因子释放。进一步研究显示甲磺司特通过抑制信号传导及转录激活蛋白5 (signal transducer and activator of transcription 5,STAT5) 及哺乳动物雷帕霉素靶标 (mammalian target of rapamycin,mTOR) 的磷酸化,下调GATA结合蛋白3 (GATA-binding protein 3,GATA3) 的表达及活性抑制Th2细胞分化。肺部过表达GATA3可以翻转甲磺司特的抗肺纤维化疗效。本实验所有动物实验均通过中国医学科学院药物研究所伦理审查委员会审查。本研究不仅阐释了甲磺司特的药理学作用机制,还为临床抗肺纤维化药物治疗提供了新的选择。
关键词:    博莱霉素      免疫      细胞因子      Th2型细胞      呼吸系统炎性疾病     
Suplatast tosilate attenuates pulmonary fibrosis by inhibiting the GATA3 induced Th2 differentiation
LIU Chang1,2, LIU Shan-shan1, LI Yun-xuan3, HUA Fang1, LÜ Xiao-xi1*
1. Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China;
2. Drug Clinical Trial Institution, Children's Hospital, Capital Institute of Pediatrics, Beijing 100020, China;
3. Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
Abstract:
Pulmonary fibrosis (PF) is a chronic respiratory inflammation disease that threatens human health. The topical immune microenvironment of lung tissue regulates progression of fibrosis. In this study, the efficacy and molecular mechanism of suplatast tosilate (ST) against PF were observed. ST is a T helper 2 (Th2) cytokine inhibitor for clinical treatment of bronchial asthma. But whether it can be applied to therapy of chronic PF and the biomechanism of ST inhibiting Th2 cytokine release are not clear. Using in vivo and in vitro experiments, we found that ST can significantly suppress the pathogenesis of chronic PF induced by multiple bleomycin injury, improve the lung function, and decrease the deposition of collagen in lung tissue. In addition, ST decreases Th2 cytokine releasing through restraining Th2 cell differentiation in the meantime, but did not influence the T helper 1 (Th1) cell differentiation and Th1 cytokine releasing. Further studies showed that ST inhibits Th2 cell differentiation by down-regulating GATA-binding protein 3 (GATA3) expression and activity through inhibiting the phosphorylation of signal transducer and activator of transcription 5 (STAT5) and mammalian target of rapamycin (mTOR). The excessive expression of GATA3 in lungs can reverse the anti-PF effect of ST. All procedures involving animal treatment were approved according to the Committee on the Ethics of Animal Experiments of the Institute of Materia Medica, Chinese Academy of Medical Sciences. Our research not only clarifies the pharmacological mechanism of ST, but also provides a new selection for clinical anti-PF drug therapy.
Key words:    bleomycin    immune    cytokine    Th2 cell    respiratory inflammatory disease   
收稿日期: 2021-07-02
DOI: 10.16438/j.0513-4870.2021-0984
基金项目: 国家自然科学基金资助项目(82173875);中国医学科学院医学与健康科技创新工程项目(2021-1-I2M-026).
通讯作者: 吕晓希,Tel/Fax:86-10-83165034,E-mail:lvxiaoxi@imm.ac.cn
Email: lvxiaoxi@imm.ac.cn
相关功能
PDF(4411KB) Free
打印本文
0
作者相关文章
刘畅  在本刊中的所有文章
刘姗姗  在本刊中的所有文章
李云炫  在本刊中的所有文章
花芳  在本刊中的所有文章
吕晓希  在本刊中的所有文章

参考文献:
[1] Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis[J]. N Engl J Med, 2018, 378: 1811-1823.
[2] Martinez FJ, Collard HR, Pardo A, et al. Idiopathic pulmonary fibrosis[J]. Nat Rev Dis Primers, 2017, 3: 17074.
[3] Gieseck RL, Wilson MS, Wynn TA. Type 2 immunity in tissue repair and fibrosis[J]. Nat Rev Immunol, 2018, 18: 62-76.
[4] She YX, Yu QY, Tang XX. Role of interleukins in the pathogenesis of pulmonary fibrosis[J]. Cell Death Discov, 2021, 7: 52.
[5] Hendeles L, Asmus M, Chesrown S. Evaluation of cytokine modulators for asthma[J]. Paediatr Respir Rev, 2004, 5 Suppl A: S107-S112.
[6] Furonaka M, Hattori N, Tanimoto T, et al. Suplatast tosilate prevents bleomycin-induced pulmonary fibrosis in mice[J]. J Pharmacol Exp Ther, 2009, 328: 55-61.
[7] Murakami T, Yamanaka K, Tokime K, et al. Topical suplatast tosilate (IPD) ameliorates Th2 cytokine-mediated dermatitis in caspase-1 transgenic mice by downregulating interleukin-4 and interleukin-5[J]. Br J Dermatol, 2006, 155: 27-32.
[8] Lv XX, Liu SS, Li YX, et al. A simple method and the application of mouse tracheal intubation[J]. Acta Pharm Sin (药学学报), 2020, 55: 1187-1192.
[9] Cao Z, Lis R, Ginsberg M, et al. Targeting of the pulmonary capillary vascular niche promotes lung alveolar repair and ameliorates fibrosis[J]. Nat Med, 2016, 22: 154-162.
[10] Flaherty S, Reynolds JM. Mouse naïve CD4+ T cell isolation and in vitro differentiation into T cell subsets[J]. J Vis Exp, 2015, 16: 52739.
[11] Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis[J]. N Engl J Med, 2012, 366: 1968-1977.
[12] Li YX, Lv XX, Liu C, et al. Pirfenidone and nintedanib inhibit the lung alveolar regeneration in chronic pulmonary fibrosis mouse[J]. Acta Pharma Sin (药学学报), 2020, 55: 861-867.
[13] Ren Q, Zhang LY, Li Z. Advances in the research of anti-organ fibrosis drugs[J]. Acta Pharm Sin (药学学报), 2020, 55: 2510-2528.
[14] Zhou L, Chong MM, Littman DR. Plasticity of CD4+ T cell lineage differentiation[J]. Immunity, 2009, 30: 646-655.
[15] Wynn TA. Fibrotic disease and the TH1/TH2 paradigm[J]. Nat Rev Immunol, 2004, 4: 583-594.
[16] Vu TN, Chen X, Foda HD, et al. Interferon-γ enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation[J]. Respir Res, 2019, 20: 206.
[17] Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells[J]. Cell, 1997, 89: 587-596.
[18] Ouyang W, Ranganath SH, Weindel K, et al. Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism[J]. Immunity, 1998, 9: 745-755.
[19] Onderdijk AJ, Baerveldt EM, Kurek D, et al. IL-4 downregulates IL-1β and IL-6 and induces GATA3 in psoriatic epidermal cells: route of action of a Th2 cytokine[J]. J Immunol, 2015, 195: 1744-1752.
[20] Zhu J, Cote-Sierra J, Guo L, et al. Stat5 activation plays a critical role in Th2 differentiation[J]. Immunity, 2003, 19: 739-748.
[21] Wan YY. GATA3: a master of many trades in immune regulation[J]. Trends Immunol, 2014, 35: 233-242.
[22] Kishikawa H, Sun J, Choi A, et al. The cell type-specific expression of the murine IL-13 gene is regulated by GATA-3[J]. J Immunol, 2001, 167: 4414-4420.
[23] Ansel KM, Djuretic I, Tanasa B, et al. Regulation of Th2 differentiation and IL4 locus accessibility[J]. Annu Rev Immunol, 2006, 24: 607-656.
[24] Izumi Y, Nakashima T, Masuda T, et al. Suplatast tosilate reduces radiation-induced lung injury in mice through suppression of oxidative stress[J]. Free Radic Biol Med, 2019, 136: 52-59.
相关文献:
1.唐进法, 王晓艳, 温强, 汤姝, 桑锋, 李伟霞, 李宇辉, 李春雨, 章从恩, 牛明, 柏兆方, 王伽伯, 肖小河.免疫应激介导的壮骨关节丸致特异质肝损伤评价[J]. 药学学报, 2017,52(7): 1033-1040
2.刘壹菲, 薛晓旭, 李正宜, 王军朋, 张祎捷.芹菜素对脾细胞中树突状细胞的成熟和功能的影响[J]. 药学学报, 2017,52(3): 397-402
3.邱磊;郭葆玉;苗红;道书艳;张冉;袁鹏群;杨旭.重组人胸腺素α原体外对IFN-γ,IFN-α及TNF-α的影响[J]. 药学学报, 2002,37(5): 326-328
4.唐进法, 王晓艳, 温强, 汤姝, 桑锋, 李伟霞, 李宇辉, 李春雨, 章从恩, 牛明, 柏兆方, 王伽伯, 肖小河.免疫应激介导的壮骨关节丸致特异质肝损伤评价[J]. 药学学报,